- $148.58m
- $194.70m
- $149.16m
Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neuronetics Appoints Nir Naor Chief Financial Officer Announces Additional Management Changes
Brief: Neuronetics And Ant Neuro Announce Strategic Collaboration To Integrate Neuronavigation With Neurostar Tms Treatment
Neuronetics Q1 revenue rises 8%, slightly beats estimates
Brief: Neuronetics Inc - Board Reviews Jorey Chernett Letter And Acknowledges Shareholder Engagement
Brief: Neuronetics Inc Initiates Workforce Reduction Impacting Up To 5% Of Employees
Brief: Neuronetics Announces Chief Financial Officer Transition
Refile: Neuronetics Q4 revenue rises, appoints Dan Reuvers as CEO
Brief: Neuronetics Q4 Gross Margin 52%
Brief: Neuronetics Appoints Dan Reuvers As President And Chief Executive Officer
Neuronetics Q3 revenue misses estimates
Brief: Neuronetics - New York Medicaid To Cover TMS Services For Adults With MDD
Neuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neuronetics Q2 Revenue USD 23 Million
Neuronetics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Neuronetics Appoints New Chief Financial Officer
Brief: Neuronetics Files For Mixed Shelf Of Up To $250 Million